Literature DB >> 6626435

Dipyridamole increases red cell deformability.

S O Sowemimo-Coker, I B Kovacs, H Pickles, A Hedges, P Turner.   

Abstract

The effects of dipyridamole on red cell filterability both in vitro and ex vivo were measured. In a balanced, randomised and double-blind trial, six healthy male and female volunteers (22-37 years) were given dipyridamole 400 mg/day or matching placebo in four divided doses for 3 days, and heparinised venous blood samples were taken 1 h after the ingestion of the last dose. Filterability of red cells was increased significantly (P less than 0.05 paired t-test) when the subjects were on dipyridamole compared with placebo. In separate experiments, 15 min incubation with 2 or 20 micrograms/ml dipyridamole in vitro was found to have no effect on the filterability of freshly prepared red cell suspensions. After 24 h storage at 4 degrees C, the filterability of red cells was significantly decreased (P less than 0.01) and this could be partially prevented by adding dipyridamole to the stored cells (P less than 0.05). These results suggest that dipyridamole has an effect on the behaviour of the red cell membrane to increase the deformability of the cells. This may contribute to its therapeutic effect.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6626435      PMCID: PMC1428025          DOI: 10.1111/j.1365-2125.1983.tb02188.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  A possible role for cyclic nucleotides in the regulation of erythrocyte shape and permeability.

Authors:  Y Yawata; H S Jacob; N Matsumoto; J White
Journal:  J Lab Clin Med       Date:  1976-10

2.  Stimulation of prostacyclin by dipyridamole.

Authors:  G Masotti; L Poggesi; G Galanti; G G Neri Serneri
Journal:  Lancet       Date:  1979-06-30       Impact factor: 79.321

3.  The effect of persantin on the phosphate compounds in erythrocytes during blood conservation.

Authors:  B Zachara
Journal:  Acta Haematol       Date:  1972       Impact factor: 2.195

4.  The effect of dipyridamole on the adenosine triphosphate level of stored human blood.

Authors:  J G Gibson; F J Lionetti
Journal:  Transfusion       Date:  1966 Sep-Oct       Impact factor: 3.157

5.  Modulation of human platelet adenylate cyclase by prostacyclin (PGX).

Authors:  R R Gorman; S Bunting; O V Miller
Journal:  Prostaglandins       Date:  1977-03

6.  Increased calcium permeability of cold-stored erythrocytes.

Authors:  J S Wiley; K E McCulloch; D S Bowden
Journal:  Blood       Date:  1982-07       Impact factor: 22.113

7.  The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3':5'-cyclic monophosphate in platelets.

Authors:  D C Mills; J B Smith
Journal:  Biochem J       Date:  1971-01       Impact factor: 3.857

8.  Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin.

Authors:  S Moncada; R Korbut
Journal:  Lancet       Date:  1978-06-17       Impact factor: 79.321

  8 in total
  4 in total

1.  In vitro and ex vivo effects of indobufen on red blood cell deformability.

Authors:  S Grasselli; R Guerciolini; V Iadevaia; P Parise; P Gresele; G G Nenci
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages.

Authors:  J Szebeni; S M Wahl; M Popovic; L M Wahl; S Gartner; R L Fine; U Skaleric; R M Friedmann; J N Weinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

Review 3.  Nucleoside salvage and resistance to antimetabolite anticancer agents.

Authors:  M Fox; J M Boyle; A R Kinsella
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

Review 4.  Red blood cell vesiculation in hereditary hemolytic anemia.

Authors:  Amr Alaarg; Raymond M Schiffelers; Wouter W van Solinge; Richard van Wijk
Journal:  Front Physiol       Date:  2013-12-13       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.